Key Highlights

  • Shares are trading down about 10.90% today following third-quarter results.
  • Revenue rose 10% year over year on an FX-neutral basis to S/1,325 million.
  • Adjusted EBITDA declined 4.6% FX-neutral, pressured by Colombia and Peru.
  • Colombia Segment Adjusted EBITDA fell 30% in local currency.
  • The company terminated a problematic oncology risk-sharing contract in Colombia.

Auna (NYSE:AUNA) shares are trading sharply lower today after the company reported third-quarter 2026 results showing Revenue growth offset by profitability pressure in two of its three markets. Auna is a leading healthcare platform in Latin America with hospital, outpatient, and health plan operations across Mexico, Peru, and Colombia. Revenue increased 10% year over year on an FX-neutral basis to S/1,325 million, while adjusted EBITDA declined 4.6% on the same basis to S/231 million.

Mexico Returns to Growth While Colombia Weighs on Results

Mexico Segment Adjusted EBITDA increased 5% year over year in local currency, marking its first quarter of growth in 2026, driven by stronger performance at the company's Monterrey Healthcare network. Colombia told a different story, with Segment Adjusted EBITDA falling 30% in local currency, primarily due to adverse medical costs under a specific oncology risk-sharing contract that significantly exceeded contractual assumptions.

Company Terminates the Problematic Colombia Contract

Auna said it has terminated the oncology risk-sharing contract to limit further exposure, noting it represented approximately 4% of Colombia's revenue, and has engaged legal counsel to review recovery options. Regulatory price caps on certain high-cost oncology medications in Colombia also weighed on profitability during the quarter.

Cash Generation and Leverage Continue to Improve

Despite the EBITDA pressure, year-to-date net cash from Operating Activities rose 62% year over year to S/713 million, while free Cash Flow increased 95% to S/626 million. The company's Leverage Ratio improved to 3.5 times, moving closer to its medium-term target of below 3.0 times.

Guidance Reflects Stable to Slightly Lower Full-Year EBITDA

Management reaffirmed full-year revenue guidance of 10% to 14% FX-neutral growth but now expects full-year adjusted EBITDA to remain broadly stable or slightly down year over year, reflecting the profitability pressures discussed, particularly in Colombia. Capital Expenditure guidance remains unchanged at approximately 4% of revenue.